跳至主要内容
临床试验/ITMCTR2100004633
ITMCTR2100004633已完成未知

A Prospective Cohort Study on the Treatment of Malignant Hydrothorax and Ascites with Recombinant Human Endostatin Based on Cold and Heat Syndrome Differentiation of Traditional Chinese Medicine

Beijing University of Chinese Medicine Shenzhen Hospital (Longgang)0 个研究点开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional study

入排标准

年龄范围
18 至 75(—)
性别
All

入选标准

  • (1) The diagnosis of malignant hydrothorax and ascites was confirmed by histopathology or cytological examination of hydrothorax and ascites. (2) There was no antineoplastic treatment within one month before treatment and no contraindications for the use of pleural and abdominal biological response regulators. (3) The estimated survival time is more than 3 months, and the KPS score is more than 60. (4) With the age of 18-75 years old, regardless of sex. (5) Informed consent was signed and volunteer for treatment.

排除标准

  • (1) Those who complicated with cardiovascular, kidney, hematopoietic system and other serious primary diseases or psychosis.
  • (2) Pregnant or lactating women, those who are allergic constitution and allergic to drugs.
  • (3) Those who cannot use drugs in accordance with the regulations, so that it's unable to judge the efficacy of treatment.

研究者

发起方
Beijing University of Chinese Medicine Shenzhen Hospital (Longgang)

相似试验

A Prospective Cohort Study on the Treatment of... | 临床试验